The study is designed to determine the safety and pharmacokinetics of multiple ascending oral doses of DB959Na in both male and female subjects.
The study results are estimated to be reported during third quarter of 2011.
The results of Phase 1a study demonstrated promising safety profile and pharmacokinetic profile that supports a once-a-day oral dose.
In addition, preclinical studies revealed that DB959 controlled glucose while raising HDL and the HDL: LDL ratio and lowering triglycerides.
DB959 regulates certain nuclear receptors PPARs that regulate the genes involved in controlling blood sugar levels and certain lipids.